The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, ARS Pharmaceuticals Inc’s stock clocked out at $17.68, down -1.12% from its previous closing price of $17.88. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 1.09 million shares were traded. SPRY stock price reached its highest trading level at $17.91 during the session, while it also had its lowest trading level at $17.51.
Ratios:
To gain a deeper understanding of SPRY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.74 and its Current Ratio is at 11.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $30.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 01 ’25 when Karas Eric sold 15,000 shares for $16.99 per share. The transaction valued at 254,860 led to the insider holds 10,315 shares of the business.
Flynn James E sold 740,149 shares of SPRY for $13,663,151 on Jun 27 ’25. The 10% Owner now owns 4,887,254 shares after completing the transaction at $18.46 per share. On Jul 01 ’25, another insider, ERIC KARAS, who serves as the Officer of the company, bought 15,000 shares for $16.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1736416512 and an Enterprise Value of 1530144768. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.88 while its Price-to-Book (P/B) ratio in mrq is 7.58. Its current Enterprise Value per Revenue stands at 15.755 whereas that against EBITDA is -57.266.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.90, which has changed by 0.78585863 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $8.91. The 50-Day Moving Average of the stock is 8.46%, while the 200-Day Moving Average is calculated to be 26.83%.
Shares Statistics:
It appears that SPRY traded 1.42M shares on average per day over the past three months and 1295500 shares per day over the past ten days. A total of 98.13M shares are outstanding, with a floating share count of 56.67M. Insiders hold about 42.30% of the company’s shares, while institutions hold 54.39% stake in the company. Shares short for SPRY as of 1752537600 were 14864141 with a Short Ratio of 10.43, compared to 1749772800 on 16577058. Therefore, it implies a Short% of Shares Outstanding of 14864141 and a Short% of Float of 24.759999999999998.
